Several large private equity firms are considering forming a consortium to pursue the asset, according to people familiar with the matter. Discussions remain at an early stage and may not lead to a deal. J&J announced plans in October to separate the slower-growing division within 18 to 24 months. At the time, Chief Financial Officer Joseph Wolk said the company was preparing for a potential spinoff but was 'open to ideas that others might have,' including a sale or alternative transaction if it delivered greater value. Private equity firms have grown more confident pursuing large-scale healthcare assets following major take-private transactions last year. Acquiring DePuy Synthes would allow sponsors to deploy significant capital into a defensive, cash-generative medical technology platform. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE...
learn more
